NEW YORK, July 12, 2017 /PRNewswire/ -- Pain Drug Development Pipeline Review, 2017
SummaryThis report provides an overview of the pain pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Osteoarthritis Pain, Migraine pain and Neuropathic Pain, therefore covering a number of the most difficult-to-treat chronic and acute pain subtypes.Osteoarthritis pain is the most common symptom associated with osteoarthritis which causes disruption of the cartilage. This further leads to rubbing of the bones against each other stimulating pain. The predisposing factors are age, joint injury, obesity and heredity. There are a total of 62 products in development for this indication, by 52 companies and two academic institutions. Key companies operating in this pipeline space include Iroko Pharmaceuticals, Aquilus Pharmaceuticals, AskAt, Astellas Pharma, Marina Biotech, Pfizer and Rottapharm Biotech.
Migraine is a disorder characterized by repeated attacks of severe headache. A migraine headache causes throbbing or pulsating pain, usually on only one side of the head. These headaches are often associated with nausea, vomiting, and extreme sensitivity to light and sound. There are a total of 76 products in development for this indication, by 49 companies and five academic institutions. Key companies operating in this pipeline space include Promius Pharma (who are fielding six pipeline products), Allergan, Amgen, Eli Lilly and Company and Klaria Pharma Holding.Neuropathic pain, or neuralgia, is a condition in which the sensory system is affected. It is commonly accompanied by tissue injury, in which the nerve fibres could be damaged resulting in the generation of abnormal signals. However, it is exhibited in a range of diseases and has no specific identifiable cause. There are a total of 249 products in development for this indication, by 163 companies and 31 academic institutions. Key companies operating in this pipeline space include Anavex Life Sciences (who are fielding five pipeline products), Algiax Pharmaceuticals, AnaBios Corp and Grunenthal GmbH.The molecular targets which are being studied overlap to only a moderate extent, and generally a different set of molecular targets is being studied in each of the three indications. Generally, there is a mixture of novel and well-established molecular targets across all three areas.Within osteoarthritis pain, prostaglandin G/H synthases 1 and 2 and the nerve growth factor receptors are being studied by the most pipeline products; while the prostaglandin receptors are frequently targeted by already approved marketed products, the nerve growth factor receptors are not. In migraine, it is the 5-hydroxytryptamine (serotonin) receptors 1D and 1B which are being most frequently studied, again reflecting the composition of the market for this indication. However, the calcitonin gene related peptide and its receptor, also very frequently targeted, are not yet present in the migraine market. Finally, the favoured targets of neuropathic pain are the sodium channel protein type 9 (Nav1.9) and the mu type opioid receptor. While the latter is already heavily targeted in the pain market, the former is not.
Scope- Which companies are the most active within the pipeline for pain therapeutics?- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?- What are the most important R&D milestones and data publications to have happened in the field of pain therapeutics?Reasons to buy- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administrationRead the full report: http://www.reportlinker.com/p04978347/Pain-Drug-Development-Pipeline-Review.htmlAbout Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.http://www.reportlinker.com
__________________________Contact Clare: [email protected]US: (339)-368-6001Intl: +1 339-368-6001
Advertisement
SummaryThis report provides an overview of the pain pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Osteoarthritis Pain, Migraine pain and Neuropathic Pain, therefore covering a number of the most difficult-to-treat chronic and acute pain subtypes.Osteoarthritis pain is the most common symptom associated with osteoarthritis which causes disruption of the cartilage. This further leads to rubbing of the bones against each other stimulating pain. The predisposing factors are age, joint injury, obesity and heredity. There are a total of 62 products in development for this indication, by 52 companies and two academic institutions. Key companies operating in this pipeline space include Iroko Pharmaceuticals, Aquilus Pharmaceuticals, AskAt, Astellas Pharma, Marina Biotech, Pfizer and Rottapharm Biotech.
Advertisement
Migraine is a disorder characterized by repeated attacks of severe headache. A migraine headache causes throbbing or pulsating pain, usually on only one side of the head. These headaches are often associated with nausea, vomiting, and extreme sensitivity to light and sound. There are a total of 76 products in development for this indication, by 49 companies and five academic institutions. Key companies operating in this pipeline space include Promius Pharma (who are fielding six pipeline products), Allergan, Amgen, Eli Lilly and Company and Klaria Pharma Holding.Neuropathic pain, or neuralgia, is a condition in which the sensory system is affected. It is commonly accompanied by tissue injury, in which the nerve fibres could be damaged resulting in the generation of abnormal signals. However, it is exhibited in a range of diseases and has no specific identifiable cause. There are a total of 249 products in development for this indication, by 163 companies and 31 academic institutions. Key companies operating in this pipeline space include Anavex Life Sciences (who are fielding five pipeline products), Algiax Pharmaceuticals, AnaBios Corp and Grunenthal GmbH.The molecular targets which are being studied overlap to only a moderate extent, and generally a different set of molecular targets is being studied in each of the three indications. Generally, there is a mixture of novel and well-established molecular targets across all three areas.Within osteoarthritis pain, prostaglandin G/H synthases 1 and 2 and the nerve growth factor receptors are being studied by the most pipeline products; while the prostaglandin receptors are frequently targeted by already approved marketed products, the nerve growth factor receptors are not. In migraine, it is the 5-hydroxytryptamine (serotonin) receptors 1D and 1B which are being most frequently studied, again reflecting the composition of the market for this indication. However, the calcitonin gene related peptide and its receptor, also very frequently targeted, are not yet present in the migraine market. Finally, the favoured targets of neuropathic pain are the sodium channel protein type 9 (Nav1.9) and the mu type opioid receptor. While the latter is already heavily targeted in the pain market, the former is not.
Scope- Which companies are the most active within the pipeline for pain therapeutics?- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?- What are the most important R&D milestones and data publications to have happened in the field of pain therapeutics?Reasons to buy- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administrationRead the full report: http://www.reportlinker.com/p04978347/Pain-Drug-Development-Pipeline-Review.htmlAbout Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.http://www.reportlinker.com
__________________________Contact Clare: [email protected]US: (339)-368-6001Intl: +1 339-368-6001
View original content:http://www.prnewswire.com/news-releases/pain-drug-development-pipeline-review-2017-300487262.html
SOURCE Reportlinker
